This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 85.5 kDa. The protein migrates as 100-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, Arginine, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 3 months under sterile conditions.
Human ACE2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human ACE2, His Tag (Cat. No. AC2-H52H8) was more than 85% and the molecular weight of this protein is around 190-220 kDa verified by SEC-MALS.
SARS-CoV-2 S1 protein, Fc Tag (Cat. No. S1N-C5255) captured on CM5 Chip via anti-human IgG Fc antibodies can bind Human ACE2, His Tag (Cat. No. AC2-H52H8) with an affinity constant of 3.79 nM as determined in SPR assay (Biacore T200) (Routinely tested).
Loaded SARS-CoV-2 S protein RBD, Fc Tag (Cat. No. SPD-C5255) on Protein A Biosensor, can bind Human ACE2, His Tag (Cat. No. AC2-H52H8) with an affinity constant of 2.16 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag (Cat. No. S1N-C5257) on AMC Biosensor, can bind Human ACE2, His Tag (Cat. No. AC2-H52H8) with an affinity constant of 2.53 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded SARS-CoV-2 S protein (R683A, R685A), His Tag (Cat. No. SPN-C52H4) on AR2G Biosensor, can bind Human ACE2, His Tag (Cat. No. AC2-H52H8) with an affinity constant of 11.4 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Authors: Maritz, Leo et al.
Journal: Bioanalysis 2021
Application: ELISA
Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity
Authors: Pratik Adhikary, Sashi Kandel, et al.
Journal: Advanced Therapeutics. 2021
Application: SPR
Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum
Authors: Fiedler S, Piziorska MA, Denninger V, et al.
Journal: ACS infectious diseases 2021
Application: Binding Assay
Authors: Narang, Dominic et al.
Journal: Journal of the American Society for Mass Spectrometry 2021
Application: HDX-MS
Authors: Zhou D, Chan JF, Zhou B, et al.
Journal: Cell Host Microbe 2021
Application: SPR
Authors: Esparza, Thomas J et al.
Journal: Scientific reports 2020
Application: Competitive Immunopanning
Antibody Signature Induced by SARS-CoV-2 Spike Protein Immunogens in Rabbits
Authors: Ravichandran S, Coyle EM, Klenow L, et al.
Journal: Sci Transl Med 2020
Application: SPR
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.
A-Z
